ANAB and TRAX Related Headlines
Go Back- AnaptysBio (ANAB) PT Raised to $66 at H.C. Wainwright
- Guggenheim on AnaptysBio (ANAB) Spinoff: 'Additional potential upside may be derived from imsidolimab in generalized pustular psoriasis'
- Anaptys Provides Update on Business Separation and Announces Fourth Quarter and Full Year 2025 Financial Results

